Autopsy report · NCT00361296

Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

“Loss of funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 2 years 4 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 8 years 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sponsor type

University, hospital or other

Conditions

Myelodysplastic Syndromes

Interventions

K562/GM-CSF cell vaccine

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• Evaluating Autologous Stromal Vascular Fraction in Subjects with Vocal Fold Scar
  “Funding loss” (97% match in meaning)
• Meru Health Program to Treat Depression in Primary Care
  “Loss of grant funding.” (89% match in meaning)
• The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC
  “Loss of external funding” (87% match in meaning)
• Mepolizumab for Eosinophilic Fasciitis
  “Funding lost from Sponsor.” (86% match in meaning)
• Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
  “Low accrual/Loss of funding” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.